Cerebrospinal fluid cells immune landscape in multiple sclerosis

Zijian Li, Yongchao Liu†, Aili Jia†, Yueran Cui and Juan Feng*

Abstract

Background: Multiple Sclerosis (MS) is a potentially devastating autoimmune neurological disorder, which characteristically induces demyelination of white matter in the brain and spinal cord.

Methods: In this study, three characteristics of the central nervous system (CNS) immune microenvironment occurring during MS onset were explored; immune cell proportion alteration, differential gene expression profile, and related pathways. The raw data of two independent datasets were obtained from the ArrayExpress database; E-MTAB-69, which was used as a derivation cohort, and E-MTAB-2374 which was used as a validation cohort. Differentially expressed genes (DEGs) were identified by the false discovery rate (FDR) value of < 0.05 and |log2 (Fold Change)|> 1, for further analysis. Then, functional enrichment analyses were performed to explore the pathways associated with MS onset. The gene expression profiles were analyzed using CIBERSORT to identify the immune type alterations involved in MS disease.

Results: After verification, the proportion of five types of immune cells (plasma cells, monocytes, macrophage M2, neutrophils and eosinophils) in cerebrospinal fluid (CSF) were revealed to be significantly altered in MS cases compared to the control group. Thus, the complement and coagulation cascades and the systemic lupus erythematosus (SLE) pathways may play critical roles in MS. We identified NLRP3, LILRB2, C1QB, CD86, C1QA, CSF1R, IL1B and TLR2 as eight core genes correlated with MS.

Conclusions: Our study identified the change in the CNS immune microenvironment of MS cases by analysis of the in silico data using CIBERSORT. Our data may assist in providing directions for further research as to the molecular mechanisms of MS and provide future potential therapeutic targets in treatment.

Keywords: Multiple sclerosis, Bioinformatics analysis, CIBERSORT, Immune microenvironment

Background

MS is one of the most common inflammatory demyelinating neurological diseases, and the disability resulting from it presents a huge social burden, putting many young adults in wheelchairs from an early age, and causing a range of problems for the family of the affected person. Though it is not actually a malignancy, MS is also sometimes known as one of the ‘nonfatal cancers’. To date, there is no medical therapeutic strategy that can cure MS. In the initial stages of MS, and also in an experimental autoimmune encephalomyelitis (EAE) animal model, following damage to the blood–brain barrier (BBB), inflammatory cells infiltrate tissues of the brain and spinal cord. Persistent inflammatory cells and cytokines in the CNS microenvironment caused by this loss of BBB integrity can promote disease progression and recurrence. Indeed, the extent of BBB permeability, which disrupts the homeostasis of the CNS immune microenvironment, is directly correlated with disease
severity [1]. According to recent reports in literature, the cells of the immune system such as M1 macrophage/microglia [2, 3], Th1 cell [4, 5], Th17 cell [6] play vital roles in exacerbating the MS disease, however, M2 macrophage/microglia [7], Th2 cell [8], regulatory T cell [9] play vital roles in ameliorating the MS disease. Furthermore, many different types of immunocytes such as B cell [10, 11], neutrophil [12], dendritic cell [13] and mast cell [14] were involved in the pathogenesis, development or relapse of MS.

CSF is a plasma-like liquid that circulates in the ventricles and sub-arachnoid space, providing the brain with nutrient delivery, waste removal, and protection from mechanical injury. Because of the ventricular neuroanatomy and the characteristics of the circulation and production of CSF, there is frequently a corresponding relationship between the CSF laboratory findings and the pathological changes of CNS. Thus CSF cytology and biochemistry is an important basis for the diagnosis of disease of brain tissue. For example, CSF laboratory tests may reveal the existence and nature of radiculopathy in the subarachnoid space, meningeal disease and inflammatory lesions of brain parenchyma. A ‘liquid biopsy’ of CSF may also be useful for detecting nervous system tumors. The detection of oligoclonal bands (OCBs), anti-myelin basic protein (MBP) antibody, and anti-myelin oligodendrocyte glycoprotein (MOG) antibody in the CSF and serum are now important diagnostic markers in the diagnosis of MS and are widely used clinically in diagnosis. However, more research is needed to fully understand how these CSF markers change over the disease progression. Therefore, it is essential and important to undertake a comprehensive analysis of the CNS immune microenvironment, of differentially expressed genes, signaling pathways, and changes in the composition of immune cells in MS, compared to those of a normal control immune microenvironment. Such analysis may provide exciting new insights in understanding normal CSF homeostasis and the pathological changes in MS.

Whether MCPcounter, TIminer or other scoring methods based on labeled genes are used, or CIBERSORT, TIMER, ImmuCellAI and other scoring methods based on cell mixture deconvolution expression characteristics, it is gene expression data that quantify the immune cell proportion. CIBERSORT [15] can quantitatively calculate the abundance of specific cell types in complex tissues, and its results have been verified by fluorescence activated cell sorting. In recent years, research into the analysis of immune microenvironment cell types has progressed, with researchers developing new methods such as CIBERSORTx [16] and xCell [17]. The analysis of immune cell subtype distribution patterns has proved of great value and has been used in many kinds of tumors [18, 19], and immune related diseases [20, 21]. However, until now, no CIBERSORT analysis of the immune cell subtype distribution pattern associated with MS has been undertaken based on CSF samples. The disease lesions, immunocytes in CSF, and the CSF supernatant which bathing the CNS tissue constitute the immune microenvironment of the MS disease together. Previous studies mainly focused on the gene expression change in CSF supernatant or the immunocytes infiltrated alteration in brain tissue lesions. This study focused on CIBERSORT analysis based on the gene transcriptional matrix of the CSF cells of both MS cases and control groups in order to find a missing link to complete the whole picture of the immune microenvironment. Moreover, exploring the changes in cell composition and gene expression levels of cells in the CSF, a part of the CNS immune microenvironment, will help us better understand the detail of the processes occurring during disease.

In this study, we explored the proportion of the immune cell types in the CSF of individuals from two microarray datasets using the CIBERSORT method, and performed a comprehensive analysis of related immune cells, genes and signaling pathways. The raw data of datasets E-MTAB-2374 and E-MTAB-69 were obtained from the EBI ArrayExpress database (https://www.ebi.ac.uk/arrayexpress), which stores data from high-throughput functional genomics experiments and makes the data available to the research community. The study of drug pathways targeting disease-related immune cells and genes will assist the development of new diagnosis and treatment strategies for MS.

**Materials and methods**

**Microarray datasets collection**

The filter search inclusion criteria were as follows: (1) search term, multiple sclerosis; (2) organism, Homo sapiens; (3) type, transcription profiling by array; and (4) dataset including MS cases and control CSF samples. The exclusion criteria were as follows: (1) dataset containing fewer than 10 MS samples and 10 control samples; (2) the profile was based on cell lines; (3) individuals who received immunomodulatory drugs; and (4) individuals with other neurological diseases of a non-inflammatory kind were used as the control population. There was no dataset in the GEO database that met the inclusion criteria. In this study, the EBI ArrayExpress functional genomics database (https://www.ebi.ac.uk/arrayexpress/) was used to acquire the gene expression profiles of MS.

The raw data of E-MTAB-69 [22] was used to obtain the derivation dataset, which included 18 other non-inflammatory neurological disorders as controls and 26 MS CSF samples. The raw data of E-MTAB-2374 [23] was used as the validation dataset, which included 13
other neurological diseases as controls and 35 MS CSF samples (15 patients who received immunomodulatory drugs were excluded, so that only 20 MS samples were finally included for further analysis). The detailed information of MS cases and control samples in these two datasets were listed in the Additional file 4: Table S1. The samples in the two datasets were detected by the array of A-AFFY-44—Affymetrix GeneChip Human Genome U133 Plus 2.0 [HG-U133_Plus_2]. Figure 1 shows the details of the study process.

Data preprocessing and DEG analysis
The raw expression profile data of these two datasets was downloaded from the EBI ArrayExpress database in CEL format (as.cel files). Bioinformatics analysis was performed using the R version 3.6.3 software. Data normalization and background correction were performed by the R package ‘affy’. Next, we converted the probe level data into gene expression values. If multiple probes corresponded to the same gene, we took the average expression value as the gene expression value. Differentially Expressed Genes (DEGs) between the MS and control groups were determined using the R package ‘limma’. Significance analysis of the microarray data was performed, with the selection criteria as follows: (1) false discovery rate (FDR) value < 0.05; (2) |log2 (Fold Change)| > 1 (fold change > 2 or < 0.5). Moreover, we used STRING and Cytoscape software version 3.8.0 to construct the PPI network.

GO functional and KEGG pathway enrichment analysis
The ‘clusterProfiler’ package in R was used to determine the biological functions of DEGs, which identified Gene Ontology (GO) biological process (BP), cellular components (CC), molecular function (MF) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment analyses. The cutoff criterion for the GO and KEGG pathway analysis were both set at adjusted p value < 0.05.

Gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA)
In this study, the open source ‘GSVA’ package for R was used to estimate variation of pathway activity over a sample population in an unsupervised manner [24], based on the microarray data. Furthermore, the ‘limma’ package for R was used to build linear models for comparing GSVA scores between MS cases and the control group. The cutoff criteria for GSVA were set as adjusted p value < 0.05 and |log2(fold change)| ≥ 0.2. Furthermore, GSEA software was used to identify differentially enriched pathways between MS cases and the control groups with significant differences. The previously annotated gene set c2.cp.kegg.v7.1.symbols.gmt was chosen as the reference gene list. The cutoff value for the GSEA was set as p value < 0.05.

Immune cell landscape analysis
CIBERSORT is a deconvolution algorithm that converts a normalized gene expression matrix into a constitutive distribution pattern of immune cells. In this study, we used the dataset E-MTAB-69 containing 26 MS cases.

---

**Fig. 1** The flow chart of the analysis procedure. MS, multiple sclerosis; CIBERSORT, cell-type identification by estimating relative subsets of RNA transcripts; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; GSEA, gene set enrichment analysis; GSVA, gene set variation analysis.
and 18 controls to estimate the ratios of 22 types of infiltrated immune cells at the onset of disease. The immune cell types were listed as follows: neutrophils, monocytes, eosinophils, M0 macrophages, M1 macrophages, M2 macrophages, resting NK cells, activated NK cells, resting dendritic cells, activated dendritic cells, resting mast cells, activated mast cells, naïve CD4+T cells, memory activated CD4+T cells, memory resting CD4+T cells, CD8+T cells, regulatory T cells, γδ T cells, follicular helper T cells, naïve B cells, and memory B cells. For each sample, the summation of the total of each of the 22 types of immune cells’ evaluated ratio was 100%. The CIBERSORT estimation result (with p value < 0.05) was thus taken as an accurate prediction of the immune cell composition. The samples that met the constraints were selected for further analysis.

**Validation of core genes, immune cells, and pathways**

The microarray data of 13 controls and 20 MS samples (without immunomodulatory treatment) from the E-MTAB-2374 dataset was used to verify the findings in the E-MTAB-69 derivation dataset. We examined the expression of core genes, immune cell alterations and DEGs enrichment pathways. A p value < 0.05 was considered to indicate a statistically significant difference. The intersection of the findings between the two datasets was considered to be real core genes, cells, and pathways.

Furthermore, we used an online digital algorithm tool—Immune Cell Abundance Identifier (ImmuneCellAI) (http://bioinfo.life.hust.edu.cn/ImmuneCellAI#!/) [25], a gene set signature-based method calculated using the single sample gene set enrichment analysis (ssGSEA), to validate CIBERSORT computational analysis data. ImmuneCellAI is a tool to estimate the abundance of 24 immune cells from gene expression dataset including RNA-Seq and microarray data, in which the 24 immune cells are comprised of 18 T-cell subtypes and 6 other important immune cells: B cell, NK cell, Monocyte, Macrophage, Neutrophil and DC.

**Statistical analysis**

Statistical analysis and graphs were performed using R software, version 3.6.2 (the R Foundation for Statistical Computing). A p value < 0.05 was considered to be statistically significant.

**Results**

**Identification of core DEGs**

The hierarchical cluster analysis heatmap showed significantly different distributions of gene expression patterns between MS cases and control samples of dataset E-MTAB-69 (Fig. 2a). Under the threshold values of FDR < 0.05 and |log2 (Fold Change)| > 1, a total of 148 DEGs (21 up-regulated and 127 down-regulated) were chosen for further analysis, as shown in Fig. 2b and Additional file 4: Table S2. The interactions among the 148 DEGs were visualized in the PPI network. We identified 111 nodes and 592 edges among the DEGs and used the Cytoscape software platform for visualization (Fig. 2c). Genes with the top 20 degree scores based on cyto-Hubba analysis were identified as core genes (Table 1 and Fig. 2d). The degree means a connectivity degree that a gene connects with other genes in the PPI network. For example, degree = 1 means the connection comes from this gene or ends up with this gene. The closer the relationship with other genes in the network, the higher the degree value of the gene.

**GO and KEGG analysis**

Then, we performed the GO and KEGG analyses to further explore the pathways in which DEGs were enriched of dataset E-MTAB-69. The GO analysis results showed that DEGs were mainly enriched in neutrophil activation, neutrophil activation involved in immune response, neutrophil degranulation, neutrophil mediated immunity and leukocyte migration, etc. The detailed top ten GO (BP, CC and MF) annotation terms are shown in Fig. 3a. The KEGG pathways of the DEGs are shown in Fig. 3b, which were mainly enriched in pathways of complement and coagulation cascades, phagosomes, transcriptional misregulation in cancer, cytokine-cytokine receptor interaction, Leishmaniasis and so on. Most of these pathways were associated with immune and inflammatory responses.

**GSVA and GAEA analysis**

GSVA results of dataset E-MTAB-69 showed that 13 pathways were significantly activated in MS, whereas 10 were inhibited (Fig. 4a and Additional file 4: Table S3). Similarly, genes in the disease group were significant highly enriched in two pathways, with 18 pathways enriched in the control group (p value < 0.05) according to the GSEA results (Fig. 4b and Additional file 4: Table S4). Seven pathways, including the ubiquitin-mediated proteolysis pathway, primary immunodeficiency pathway, SLE pathway, lysosome pathway, glycosaminoglycan degradation pathway, complement and coagulation cascades pathway, and the arrhythmogenic right ventricular cardiomyopathy (ARVC) pathway overlapped in both the GSVA and GSEA results, and are listed in Table 2. Furthermore, only two pathways (the complement and coagulation cascades pathway and the SLE pathway) in the KEGG pathway enrichment results of dataset E-MTAB-69 DEGs were overlapped with intersection of the GSVA and GSEA results.
Immune cell type pattern alteration in MS cases

The histogram shows the general distribution of various immune cells in each sample of dataset E-MTAB-69 (Fig. 5a). Different colors represent different types of immune cells. The height of each color represents the percentage of such cells in the sample, and the sum of the percentage of various immune cells equals 1. It was observed that the main infiltrating cells were: T cells gamma delta, T cells CD4 memory resting, T cells CD4 naïve, T cells CD8, T cells CD4 memory activated, and...
M2 Macrophages. Due to the limitations of the CIBERSORT algorithm, the distribution of some immune-cell subsets with low abundance expression in CSF samples of MS was not fully revealed. The proportion of immune cells in the comparison samples of the two groups showed individual differences. Cluster analysis of infiltrating immune cells in the disease and control data was an important means of determining the pathological processes and immune regulation mechanisms, as is shown in Fig. 5b. MS samples generally contained a lower proportion of eosinophils ($p = 0.004$), macrophages M2 ($p = 0.003$), resting mast cells ($p = 0.006$), monocytes ($p < 0.001$), neutrophils ($p = 0.026$), activated NK cells ($p < 0.001$) than control samples; whereas the plasma cells ($p < 0.001$) fraction was relatively higher (Fig. 5c). The boxplot (Fig. 5d) shows the details of the significantly altered immune cell proportion between the MS and control groups.

Validation of CNS immune microenvironment alteration
In Fig. 6a, the hierarchical cluster analysis heatmap showed significantly different distributions of gene expression patterns between the MS cases and control samples of the validation cohort. Under the threshold of FDR < 0.05 and $|\log2 \text{(Fold Change)}| > 1$, a total of 150 DEGs (53 up-regulated and 97 down-regulated) were chosen for further analysis (Fig. 6b and Additional file 4: Table S5). Then, we found that eight genes were overlapped in the top 20 hub genes of the derivation cohort and 150 DEGs of the validation cohort. The expression details are listed in Table 3. These eight genes were recognized as core genes involved in MS disease. As shown in Fig. 6c(i–(viii)), we also found that NLRP3, LILRB2 C1QB, CD86, C1QA, CSF1R, IL1B and TLR2 were downregulated in the MS samples. The scatter plots of eight genes were consistent with the derivation cohort analysis results. The KEGG pathways of

| Gene symbol | LogFC | P.Value | Adj.P.Value | Degree | Up/down-regulated |
|-------------|-------|---------|-------------|--------|------------------|
| TLR2        | −1.402720222 | 3.46E−05 | 0.000996373 | 38 | Down-regulated |
| CXCL8       | −1.991659081 | 1.66E−05 | 0.000623919 | 38 | Down-regulated |
| IL1B        | −1.353392774 | 5.32E−06 | 0.000322284 | 38 | Down-regulated |
| FN1         | −1.534988876 | 2.41E−05 | 0.000796163 | 34 | Down-regulated |
| CSF1R       | −1.212137423 | 5.36E−05 | 0.001354478 | 34 | Down-regulated |
| CD86        | −1.086235688 | 0.000162393 | 0.002835159 | 32 | Down-regulated |
| CD163       | −1.345148553 | 0.000387759 | 0.005193712 | 29 | Down-regulated |
| CD14        | −1.899109363 | 7.01E−05 | 0.001644275 | 28 | Down-regulated |
| C3AR1       | −1.333582312 | 6.91E−05 | 0.001631076 | 28 | Down-regulated |
| FOS         | −1.088599141 | 0.000691142 | 0.007925829 | 28 | Down-regulated |
| PTGS2       | −1.58185487 | 5.97E−06 | 0.00348936 | 26 | Down-regulated |
| LILRB2      | −1.260703038 | 2.49E−05 | 0.000803783 | 25 | Down-regulated |
| C1QB        | −1.677793359 | 0.000312054 | 0.00446939 | 23 | Down-regulated |
| MRC1        | −1.399146821 | 0.000212776 | 0.00339139 | 23 | Down-regulated |
| C1QA        | −1.395713692 | 0.002766721 | 0.020479401 | 22 | Down-regulated |
| FCGR2A      | −1.580725252 | 7.77E−06 | 0.00400066 | 22 | Down-regulated |
| AIF1        | −1.043775506 | 5.30E−07 | 7.89E−05 | 21 | Down-regulated |
| NLRP3       | −1.127666613 | 3.53E−10 | 8.93E−07 | 21 | Down-regulated |
| CCL3        | −1.113448799 | 0.000134268 | 0.00250386 | 21 | Down-regulated |
| MINDA       | −1.032416671 | 3.19E−05 | 0.000952134 | 20 | Down-regulated |

Down-regulated down-regulated in MS cases
DEGs are shown in Fig. 6d, which were mainly enriched in immune-associated pathways, such as hematopoietic cell lineage, cytokine-cytokine receptor interaction, cell adhesion molecules, complement and coagulation cascades, intestinal immune network for IgA production, B cell receptor signaling pathway, SLE pathway and so on. In addition, we found that two pathways, the complement and coagulation cascades pathway and the SLE pathway, were overlapped in these KEGG results and in the former functional enrichment analysis such as in the GSEA, GSVA and KEGG results of the derivation cohort.

We found that MS samples generally contained a lower proportion of eosinophils \( (p = 0.007) \), macrophages M2 \( (p = 0.009) \), monocytes \( (p < 0.001) \), neutrophils \( (p = 0.027) \) than the control samples; whereas the plasma cells \( (p < 0.001) \), B memory cells \( (p = 0.034) \), naive B cells \( (p < 0.001) \), follicular helper T cells \( (p = 0.012) \) and gamma delta T cells \( (p = 0.04) \) fractions were relatively higher (Fig. 7 and Additional file 1: Figure S1). Five types
of immune cells (plasma cells, monocytes, M2 macrophages, neutrophils and eosinophils) in the cerebrospinal fluid (CSF) were shown to be significantly different between the MS and control groups.

Furthermore, the combined ImmucellAI online analysis results of dataset E-MTAB-69 (as shown in Additional file 2: Figure S2) and E-MTAB-2374 (as shown in Additional file 3: Figure S3) indicated that CD8+ naïve T cell, Th17, effector memory T (Tem) cell, mucosal-associated invariant T (MAIT) cell, dendritic cell (DC), B cell, Monocyte, Macrophage and Neutrophil had abundance differences between MS and control groups. This online tool is mainly for 18 T cell subtype and 6 other immunocytes abundance prediction, so its immune cell classification is not one-to-one correspondence with our CIBERSORT analysis. The results from these two methods roughly matched, however, were still needed further experimental verification in the future.

**Discussion**

MS is an autoimmune disease characterized by demyelination of the CNS and infiltration of inflammatory cells. The condition relapses and progresses, often leading to lifelong disabilities. During the pathogenesis of multiple sclerosis, a variety of immune-related molecules and pathways are altered. We identified eight core molecules in our findings (NLRP3, LILRB2, C1QB, CD86, C1QA, CSF1R, IL1B and TLR2), all of which, with the exception of C1QB, have previously been reported to be associated with MS or EAE. However, previous research has focused on the protein level alteration in the CNS tissue or supernatant of CSF [26–32].

Recently, Hammond and colleagues [26] found that complement C1q A chain (C1qA) mRNA expression, and C1q protein expression, were both significantly increased in the hippocampus of EAE mice compared to control groups. Expression of the transcript for C1qA was noted in the neurons in the MS cortical and deep grey matter [33]. The variant rs158772 of C1QA was associated with a 71% increase in risk of sustained low-contrast letter acuity loss, which indicated visual system degeneration in MS [34]. Previous studies have reported that neurological damage and degenerative changes could influence the expression of complement C1q B chain (C1qB). Experimental lesions (kainic acid-induced) in the hippocampus and in other brain regions increased C1qB mRNA [35]. Grewal and colleagues found that C1qB mRNA increases in association with neurodegeneration in sporadic amyotrophic lateral sclerosis (ALS) [36]. In addition, C1q deficiency caused by the splicing mutation in the C1qB gene is closely correlated with the development of SLE [37, 38].

Furthermore, an important protein of the innate immune system, nucleotide-binding leucine-rich repeat family pyrin domain containing 3 (NLRP3) has been reported to mediate pyroptosis, and to be associated with various autoimmune disorders such as neuromyelitis optica spectrum disorder (NMOSD) and MS [39]. Recently, our team [27] as well as many other researchers [28, 29] have found that the NLRP3-mediated innate

| Pathway | GSVA logFC | GSVA Adj. P.val | GSVA NES | GSVA p-val | GSEA NES | GSEA p-val |
|---------|------------|----------------|----------|-----------|----------|-----------|
| KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS | 0.257353 | 0.000123 | 1.601199 | 0.018443 |
| KEGGPRIMARY_IMMUNODEFICIENCY | 0.256664 | 0.014024 | 1.54737 | 0.032389 |
| KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS | −0.30003 | 0.014921 | −1.46851 | 0.039293 |
| KEGG_LYSOSOME | −0.26996 | 0.00536 | −1.5659 | 0.038536 |
| KEGG_GLYCOSAMINOGLYCAN_DEGRADATION | −0.32315 | 0.000742 | −1.68337 | 0.005941 |
| KEGG_COMPLEMENT_AND_COAGULATIONCASCADES | −0.36335 | 1.77E−06 | −1.54136 | 0.005917 |
| KEGG_ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARIDIOMYOPATHY_ARVC | −0.20114 | 0.003886 | −1.47921 | 0.008163 |

NES Normalized Enrichment Score

**Fig. 5** The landscape of immune cell distributed pattern in MS and control groups of dataset E-MTAB-69. a Histogram of the fraction of 22 kinds of immune cell proportions in MS and control groups. X axis: each E-MTAB-69 sample; Y axis: percentage of each kind of immune cells. b Heatmap of 22 immune cell proportions in MS and control groups. c Violin plot shows the differences of 22 immune cell proportions between two groups. Red color represents MS cases, blue color represents controls. d Boxplot of comparisons of significantly altered immune cell proportion between two groups. Red color represents MS cases, blue color represents controls. *P < 0.05, **P < 0.01, ***P < 0.001 compared to the control group.
immune pathways may be a novel target for future treatments for MS. As a consequence of NLRP3 inflammasome activation, the expression of inflammatory genes IL1B increased in CNS tissues taken from cases with MS and from animal models with EAE [40]. Another important study demonstrated that patients with high IL1B gene levels progressed significantly faster compared to primary progressive multiple sclerosis (PPMS) patients with low IL1B expression levels in peripheral blood mononuclear cells (PBMCs), which indicated that IL1B could be a prognostic biomarker in patients with PPMS [41].

Using quantitative RT-PCR, leukocyte immunoglobulin-like receptor B2 (LILRB2), also called immunoglobulin-like transcript 4 (ILT4), has been reported to be upregulated in active lesions in the MS brain compared to the control brain [42]. In addition, LILRB2 was also induced in monocytes by IFN beta treatment in vitro, and led to a beneficial effect in MS.

Recently, Hagan and colleagues found that colony-stimulating factor-1 receptor (CSF1R) was elevated in the CNS tissue of MS cases with progressive disease [30]. Furthermore, their research demonstrated that CSF1R inhibition could reduce harmful microglial proliferation, modulate microglial phenotypes and reduce subsequent demyelination and neurodegeneration. CSF1R gene mutations were reported to be associated with hereditary diffuse leukoencephalopathy with spheroids (HDLS) which led to demyelination and axonal degeneration with spheroids of the CNS [43, 44], presenting as primary progressive MS.

It is known that the expression of Toll-like receptor 2 (TLR2) is increased in CNS tissues [31], and even in infiltrated inflammatory cells in the CNS [45] taken from cases with MS and EAE animal models, as well as in the peripheral blood mononuclear cells (PBMCs) [46]. Enhanced TLR2 responsiveness plays a critical role in the pathogenesis of MS [47], and TLR2 could inhibit the maturation and remyelination of oligodendrocyte precursor cells [48]. Reducing innate immune signals by inducing TLR2 tolerance may be a novel approach to alleviating inflammation and repairing myelin sheaths in MS [49].

The CD86 molecule (also known as B7-2) is expressed both in MS lesions and inflammatory infaracts, mainly on macrophages [32]. A study found that CD86 mRNA in the CSF cells of MS cases showed no significant difference from that of a control group [50]. However, another study reported that the costimulatory molecule CD86 expressed by T cells in CSF was low in patients with MS compared to noninflammatory control subjects [51], which is a similar finding to ours. Moreover, this study focused on transcriptional level analysis of the CSF cells of both MS cases and control groups in order to find a missing part to complete the picture of the immune microenvironment. CSF cell counts are low, especially in individuals without sustained inflammation, which may account for why CSF cell expression levels are rarely reported.

It is of interest that these eight genes were downregulated in the CSF cells, which was in contrast to the gene expression trends in CSF supernatant and in lesions. We postulated that the gene expression changes in CSF cells are due to the negative feedback regulation of the immune microenvironment, and occur in order to maintain homeostasis. Furthermore, we hypothesized that these molecular changes may be related to protein degradation and activation of the ubiquitin–proteasome pathway, which is consistent with our GSVA and GSEA findings (Fig. 4 and Table 2). The cells in CSF, disease lesions, and the CSF supernatant which bathed the CNS tissue together constitute the immune microenvironment of the disease. As the Chinese saying goes, ‘pull one hair, and the whole body moves’; in other words, a slight change will affect everything else. Our study suggests that the expression of related molecules in the cells of the CSF also changes according to the compositional changes of the CSF. Furthermore, our results are consistent with the findings of the original microchip research [22], such as the findings that B cell maturation factor TNF receptor superfamily member 17 (TNFRSF17), and POU class 2 homeobox associating factor 1 (POU2AF1) which is involved in Ig gene transcription, were highly expressed in MS, while AIF1 was down expressed in MS (see Additional file 4: Table S2 for details). Previous studies have indicated that POU2AF1 is a B-cell-specific transcriptional co-activator, which directly bound to TNFRSF17 and enhance its transcription [52], and AIF1 could induce a M2-like phenotype of macrophages [53]. Our results indicated that TNFRSF17, POU2AF1 upregulated and plasma cells increased in MS cases, AIF1 downregulated and M2 macrophages decreased in MS cases. The trend
of gene expression and the trend of cell proportion were mutually verified, which also coincided with achievements of predecessors [52, 53] on this point and showed credibility of the method we used. The findings from the E-MTAB-69 dataset will be intersected with those from E-MTAB-2374, which is equivalent to further expanding the sample size and searching for common differentially expressed genes, which is different from the focus of the original microchip research.

Our study demonstrated that the complement and coagulation cascades pathway and the SLE pathway were dysregulated in MS cases [22]. MS and SLE are common autoimmune diseases and may have a shared pathogenesis. Previous research [54] found that the occurrence and development of these two autoimmune diseases may be associated with lysosomes and phagocytosis, which leads to abnormal immune-related reactions and hence causes disease. Moreover, in 2019, Magliozzi and colleagues found that intrathecal dysregulation of complement and coagulation cascade pathways, as well as B-cell and monocyte activity, are strictly correlated with cortical damage at the early stages of MS [55]. Indeed, this field is the subject of increasing attention from researchers. Koudriavtseva and colleagues have undertaken a multicenter, prospective, controlled study to determine the exact links between activation of the coagulation/complement system and cerebral hypoperfusion in RRMS cases [56]. It has been suggested that interfering with the coagulation system might provide a novel therapeutic target in the treatment of MS and demyelinating diseases.

In this study, we used the CIBERSORT algorithm to analyze gene expression data to determine the immune cells ratio alteration in MS. We found that, in the CSF of MS cases, plasma cells increased, and monocytes decreased [22], a finding which corresponded with the speculative results of original microchip research. However, changes in the ratio of M2 macrophages, eosinophils and neutrophils were not mentioned by them and worthy of further experimental research.

The immune cells and immune reactions play a vital role in MS progress. The CIBERSORT analysis could convert the expression matrix into the immunocytes fraction matrix, which is helpful for better understanding the pathological process of diseases, especially immune-related diseases. Single-cell transcriptomics is an emerging technology which could elucidate the heterogeneity of complex tissues. Single-cell analysis of cells in CSF could help us to discover new and unknown populations of cells [41]. However, because of its high cost, single cell analysis technology has so far not been widely used, and its clinical application is limited. The accuracy of CIBERSORT has been validated by fluorescence activated cell sorting (FACS) technique, and before single-cell sequencing is widely available, CIBERSORT will be a simple and effective method to investigate immunocyte pattern of CSF in MS.

Although we have found and verified our research results with two independent datasets, we have to admit that there are some limitations in current study. First, this study is based on two public datasets uploaded some years ago, of which the complete follow-up information of clinical samples is lacked. Second, a patient’s first clinical episode of neurological symptoms is often diagnosed as clinical isolated syndrome (CIS), and at the initial diagnosis, testing for oligoclonal bands and other demyelinating related markers is undertaken to differentiate the patient from Neuromyelitis optica (NMO) or other diseases. The diagnosis of MS is confirmed by the recurrent nature of the disease, with the extended course of treatment determined by imaging results and clinical symptoms. Therefore, there are some limitations to simply obtaining clinical CSF samples. Finally, our findings based on retrospective bioinformatics analysis should be verified by following up CIS patients, cell and animal experiments in the future.

| Gene symbol | logFC | t  | PValue | adj. PVal | Up/down-regulated |
|-------------|-------|----|--------|----------|-------------------|
| NLRP3       | 1.051208 | -3.717949 | 0.0007216 | 0.0330639 | Down-regulated    |
| CD86        | 1.058162 | -4.334 | 0.0001233 | 0.0212309 | Down-regulated    |
| C1QB        | 1.145768 | -3.513766 | 0.0012729 | 0.0415789 | Down-regulated    |
| LILRB2      | 1.147991 | -3.781941 | 0.0006028 | 0.0308922 | Down-regulated    |
| TLR2        | 1.245801 | -4.140113 | 0.0002166 | 0.024029 | Down-regulated    |
| C1QA        | 1.285648 | -3.447825 | 0.0015253 | 0.0448478 | Down-regulated    |
| CSF1R       | 1.331567 | -4.240982 | 0.0001617 | 0.0222183 | Down-regulated    |
| IL1B        | 1.447641 | -3.834274 | 0.0005199 | 0.0292885 | Down-regulated    |

*Table 3 The expression of the 8 genes overlapped in top 20 hub genes of derivation cohort and 150 DEGs of validation cohort*
Conclusions
In summary, our study is the first to use the CIBERSORT method to analyze the immune cell subtypes distribution pattern in CSF samples of MS. Our study attempted to better understand the alteration of the microenvironment in, and the cause of, MS. More in-depth research of these core genes, pathways and differential immune cells may further uncover the underlying mechanisms and pathological process of MS.

Abbreviations
BBB: Blood–brain barrier; CIBERSORT: Cell-type identification by estimating relative subsets of RNA transcripts; CIS: Clinical isolation syndrome; CNS: Central nervous system; CSF: Cerebrospinal fluid; EAE: Experimental autoimmune encephalomyelitis; FACS: Fluorescence activated cell sorting; GO: Gene Ontology; GSEA: Gene set enrichment analysis; GSVA: Gene set variation analysis; HDLS: Hereditary diffuse leukoencephalopathy with spheroids; KEGG: Kyoto Encyclopedia of Genes and Genomes; MBP: Myelin basic protein; MOG: Myelin oligodendrocyte glycoprotein; MS: Multiple sclerosis; NES: Normalized Enrichment Score; OCB: Oligoclonal bands; SLE: Systemic lupus erythematosus; TLR2: Toll-like receptor 2.
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12967-021-02804-7.

Additional file 1: Figure S1. Violin plot of significant differential immune cells in MS and control groups. The control group is shown in blue and MS group is shown in red.

Additional file 2: Figure S2. The abundance differences of immune cells between MS and control groups in dataset E-MTAB-69 by the application of ImmuCellAI. 24 immune cell types including 18 T-cell subsets and 6 other important immune cells: CD4+ naive cell, CD8+ naive cell, cytotoxic T (Tc) cell, exhausted T (TEx) cell, type 1 regulatory T (Tr1) cell, natural regulatory T (nTreg) cell, induced regulatory T (iTreg) cell, Th1, Th2, Th17, T follicular helper (Tfh) cell, central memory T (Tcm) cell, effector memory T (Tem) cell, natural killer T (NKT) cell, mucosal-associated invariant T (MAIT) cell, gamma delta Tgd cell, CD4+ T cell, CD8+ T cell, dendritic cell (DC), B cell, monocyte, macrophage, natural killer (NK) cell and neutrophil. A p value < 0.05 was considered to indicate a statistically significant difference. Red color represents MS case, blue color represents control group.

Additional file 3: Figure S3. The abundance differences of immune cells between MS and control groups in dataset E-MTAB-2374 by the application of ImmuCellAI. A p value < 0.05 was considered to indicate a statistically significant difference. Red color represents MS case, blue color represents control group.

Additional file 4: Table S1. The information of control samples in these two datasets. Table S2. The differentially expressed genes of dataset E-MTAB-69. Table S3. GSVA results of the KEGG gene-set enriched in samples of derivation dataset (MS Vs Control). Table S4. GSEA results of the most of the significantly altered pathways were activated in the derivation dataset. Table S5. The differentially expressed genes of dataset E-MTAB-2374.

Acknowledgements
We thank Lu Yin in Tongji University School of Medicine, who shared their R code (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214409/bmiv/Data_Sheet_1.zip) used in their study generously to the public. We used part of their R code to draw boxplot.

Authors’ contributions
ZL designed research, analyzed data, created the figures and tables, and wrote the manuscript. YL, AJ and YC helped to revise the original manuscript. JF provided final critical revisions and conceptual support. All authors read and approved the final manuscript.

Funding
This work was supported financially by the National Natural Science Foundation of China (Grant Number 81771271), Outstanding Scientific Fund of Shengjing Hospital, study on the epigenetic molecular mechanism of tanshi-none IA for the treatment of EAE, BBB destruction, and inflammatory immune responses funded by the Science and Technology Department of Liaoning Province (2018225002) to Juan Feng and 345 Talent Project of Shengjing Hospital of China Medical University to Zijian Li.

Data availability
The data used to support the findings of this study are available from the corresponding author upon request.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors have no conflicts of interest to declare.

Received: 30 December 2020 Accepted: 19 March 2021
Published online: 25 March 2021

References
1. Fabis MJ, Scott GS, Kean RB, Koprowski H, Hooper DC. Loss of blood-brain barrier integrity in the spinal cord is common to experimental allergic encephalomyelitis in knockout mouse models. Proc Natl Acad Sci USA. 2007;104:5656–61.
2. Chu F, Shi M, Zheng C, Shen D, Zhu J, Zheng X, et al. The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neuroimmunol. 2018;318:1–7.
3. Jackle K, Zeis T, Schaeren-Wiemers N, Junkert A, van der Meer F, Kramann N, et al. Molecular signature of slowly expanding lesions in progressive multiple sclerosis. Brain. 2020;143:2073–88.
4. Guan H, Singh UP, Rao R, Mrelashvili D, Sen S, Hao H, et al. Inverse correlation of expression of microRNA-140-5p with progression of multiple sclerosis and differentiation of encephalitogenic T helper type 1 cells. Immunology. 2016;147:488–98.
5. Zhang J, Cheng Y, Cui W, Li M, Li B, Guo L. MicroRNA-155 modulates Th1 and Th17 cell differentiation and is associated with multiple sclerosis and experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014;266:56–63.
6. Moser T, Akgun K, Proschmann U, Sellner J, Ziemssen T. The role of Th17 cells in multiple sclerosis: therapeutic implications. Autoimmun Rev. 2020;19:102647.
7. Batchu S. Progressive multiple sclerosis transcriptome deconvolution indicates increased M2 macrophages in inactive lesions. Eur Neurol. 2020;83:433–5.
8. Andalib A, Doulabi H, Najafi M, Tazhibi M, Rezaie A. Expression of chemokine receptors on Th1/Th2 CD4+ lymphocytes in patients with multiple sclerosis. Iran J Immunol. 2011;8:1–10.
9. Goverman JM, Regulatory T. Cells in multiple sclerosis. N Engl J Med. 2021;384:578–80.
10. Ramesh A, Schubert RD, Greenfield AL, Dandekar R, Loudermilk R, Sabinino JJ Jr, et al. A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis. Proc Natl Acad Sci USA. 2020;117:22932–43.
11. Jelacic C, Sospedra M, Martin R. When a T cell engages a B cell: novel insights in multiple sclerosis. Swiss Med Wkly. 2020;150:w20330.
12. Bondt M, Hellings N, Opdenakker G, Stromf S. Neuropilins underesti- mated players in the pathogenesis of multiple sclerosis (MS). Int J Mol Sci. 2020;21: 1.
13. Link H, Huang YM, Xiao BG. Dendritic cells in experimental aller- genic encephalomyelitis and multiple sclerosis. J Neuroimmunol. 1999;100:102–10.
14. Elieh-Ali-Komi D, Cao Y. Role of Mast Cells in the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Clin Rev Allergy Immunol. 2017;52:436–45.
15. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453–7.
16. Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37:773–82.
17. Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18:220.
18. Zhu N, Hou J. Assessing immune infiltration and the tumor microenvi- ronment for the diagnosis and prognosis of sarcoma. Cancer Cell Int. 2020;20:577.
19. Wang P, Zhang J, He S, Xiao B, Peng X. SLC39A1 contribute to malignant progression and have clinical prognostic impact in gliomas. Cancer Cell Int. 2020;20:573.
20. Chen H, Chen C, Yuan X, Xu W, Yang MQ, Li Q, et al. Identification of immune cell landscape and construction of a novel diagnostic nomogram for Crohn’s Disease. Front Genet. 2020;11:423.
21. Xin Y, Zhang S, Deng Z, Zeng D, Li J, Zhang Y. Identification and verifica-
tion immune-related regulatory network in acne. Int Immunopharmacol.
2020;89:107083.

22. Brynedal B, Khademis M, Wallstrom E, Hillert J, Olsson T, Duvezelt K. Gene
expression profiling in multiple sclerosis: a disease of the central nervous
system, but with relapses triggered in the periphery? Neurobiol Dis.
2010;37:613–21.

23. Muller AM, Jun E, Conlon H, Sadig SA. Cerebrospinal hepatic growth
factor levels correlate negatively with disease activity in multiple sclerosis.
J Neuroimmunol. 2012;251:80–6.

24. Hanzelmann S, Castelo R, Gunney J. GSVA: gene set variation analysis for
microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.

25. Miao YR, Zhang Q, Lei Q, Luo M, Xie YG, Wang H, et al. ImmuCellAI: a
unique method for comprehensive T-cell subsets abundance prediction and
its application in cancer immunotherapy. Adv Sci. 2020;7:1902880.

26. Hammond JW, Bellizzi MJ, Ware C, Qiu WQ, Saminathan P, Li H, et al.
Complement-dependent synapse loss and microgliosis in a mouse
model of multiple sclerosis. Brain Behav Immun. 2020;87:39–50.

27. Liu F, Li Z, He X, Yu H, Feng J. Ghrelin Attenuates Neuroinflammation and
demyelination in experimental autoimmune encephalomyelitis involving
NLRP3 inflammasome signaling pathway and pyroptosis. Front Pharma-
col. 2019;10:1320.

28. Wang X, Li B, Liu L, Zhang L, Ma T, Guo L. Nicotinamide adenine dinucleo-
tide treatment alleviates the symptoms of experimental autoimmune
encephalomyelitis by activating autophagy and inhibiting the NLRP3
inflammasome. Int Immunopharmacol. 2020;90:107092.

29. Gutierrez-Miranda B, Gallardo I, Melliou E, Cabero I, Alvarez Y, Magiatis P,
et al. Oleacein attenuates the pathogenesis of experimental autoimmune
encephalomyelitis through both antioxidant and anti-inflammatory
effects. Antioxidants (Basel). 2020;9:1.

30. Hagan N, Kane JL, Grover D, Woodworth L, Madore C, Saleh J, et al. CSF1R
signaling is a regulator of pathogenesis in progressive MS. Cell Death
Dis. 2020;11:904.

31. Kwislaz AJ, Todd LS, Duran-Malle JC, Schrama AEW, Mitten EH, Larson
TA, et al. Experimental autoimmune encephalomyelitis (EAE)-induced hip-
pocampal neuroinflammation and memory deficits are prevented with the
non-opioid TLR2/TLR4 antagonist (+)-naltrexone. Behav Brain Res.
2021;396:112896.

32. Windhagen A, Newcombe J, Dangond F, Strand C, Woodroffe MN, Cuz-
ner ML, et al. Expression of costimulatory molecules B7–1 (CD80), B7–2
(CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp
Med. 1995;182:1985–96.

33. Watkins LM, Neal JW, Loveless S, Michalidou I, Ramaglia V, Rees ML, et al.
Complement is activated in progressive multiple sclerosis cortical grey
matter lesions. J Neuroinflammation. 2016;13:161.

34. Fitzgerald KC, Kim K, Smith MD, Aston SA, Fioravanti N, Rothman AM,
et al. Early complement genes are associated with visual system degen-
eration in multiple sclerosis. Brain. 2019;142:2272–36.

35. Pasinetti GM, Johnson SA, Rozovskiy I, Lampert-Etchells M, Morgan DG,
Gordon MN, et al. Complement C1qB and C4 mRNA responses to lesion-
ing in rat brain. Exp Neurol. 1992;118:17–25.

36. Grewal RP, Morgan TE, Finch CE. C1qB and clusterin mRNA increase in
association with neurodegeneration in sporadic amyotrophic lateral
neuropathy. Neurosci Lett. 1999;271:65–7.

37. Higuchi Y, Shimizu J, Hatanaka M, Kitano E, Kitamura H, Takada H, et al.
The identification of a novel splicing mutation in C1qB in a Japanese
patient with lupus nephritis inhibit C1q binding to IgG and CRP.
Immunobiology. 2012;217:684–91.

38. Radanova M, Vasilev V, Delyska B, Kishore U, Ikonomov V, Ivanova D.
Anti-C1q autoantibodies specific against the globular domain of the
C1qB-chain from patient with lupus nephritis inhibit C1q binding to IgG
and CRP. Immunobiology. 2012;217:684–91.

39. Peng Y, Chen J, Dai Y, Jiang Y, Qiu W, Gu Y, et al. NLRP3 level in cerebro-
spinal fluid of patients with neuromyelitis optica spectrum disorders:
Increased levels and association with disease severity. Mult Scler Relat
Disord. 2019;39:101888.

40. Boghazian R, McKenzie BA, Saito LB, Mehta N, Branton WG, Lu J, et al.
Suppressed oligodendrocyte steroidogenesis in multiple sclerosis: Impli-
cations for regulation of neuroinflammation. Glia. 2017;65:1500–606.

41. Malhotra S, Costa C, Eixarch H, Keller CW, Amman L, Martinez-Navadocha
H, et al. NLRP3 inflammasome as prognostic factor and therapeutic
target in primary progressive multiple sclerosis patients. Brain.
2020;143:141–30.

42. Waschbisch A, Sanderson N, Krumholz M, Vlad G, Theil D, Schwab S,
et al Interferon beta and vitamin D synergize to induce immunoregula-
tory receptors on peripheral blood monocytes of multiple sclerosis
patients. PLoS ONE. 2014;9:e115488.

43. Inui T, Kawai T, Fujita K, Kawamura K, Mitsuji T, Ofracchio A, et al.
A new CSF1R mutation presenting with an extensive white matter
lesion mimicking primary progressive multiple sclerosis. J Neurol Sci.
2013;334:192–5.

44. Sundal C, Baker M, Karranen V, Gustavson M, Bedri S, Glaser A, et al.
Hereditary diffuse leuкоencephalopathy with spheroids with phenotype of
primary progressive multiple sclerosis. Eur J Neurol. 2015;22:328–33.

45. Jafarzadeh A, Nemati M, Khormaldelazad H, Misraheyfey A. The Toll-like
Receptor 2 (TLR2)-related immunopathological responses in the multiple
sclerosis and experimental autoimmune encephalomyelitis. Iran J Allergy
Asthma Immunol. 2019;18:230–50.

46. Noorbaksh SM, Razavi A, Moghadam NB, Saadat P, Hoseini M, Aghaza-
deh Z, et al. Effects of guluronic acid (G2013) on gene expression of TLR2,
TLR4, MyD88, TNF-alpha and CDS2 in multiple sclerosis under in vitro
conditions. Immunopharmacol Immunotoxicol. 2019;41:586–90.

47. Fujisawa M, Anstadt EJ, Flynn B, Morse K, Ng C, Paczkowski P, et al.
Enhanced TLR2 responses in multiple sclerosis. Clin Exp Immunol.
2018;193:313–26.

48. Sloane JA, Batt C, Ma Y, Harris ZM, Trapp B, Vartanian T. Hyaluronan blocks
oligodendrocyte progenitor maturation and remyelination through TLR2.
Proc Natl Acad Sci USA. 2010;107:11555–60.

49. Wasko NJ, Kulak MH, Paul D, Nicaise AM, Yeung ST, Nichols FC, et al.
Systemic TLR2 tolerance enhances central nervous system remyelina-
tion. J Neuroinflammation. 2019;16:158.

50. Monteyne P, Guillaume B, Sindjic CJ. B7–1 (CD80), B7–2 (CD86), and
transforming growth factor-beta mRNA expression in CSF and peripheral
blood mononuclear cells from multiple sclerosis patients. J Neuromyel.
1998:91:198–203.

51. Sellebjerg F, Jensen J, Ryder LP. Costimulatory CD80 (B7–1) and CD86
(B7–2) on cerebrospinal fluid cells in multiple sclerosis. J Neuroimmunol.
2020;396:112896.

52. Zhao C, Inoue J, Imoto I, Otsuki T, Iida S, Ueda R, et al. POU2AF1, an ampli-
fier of primary progressive multiple sclerosis. J Transl Med          (2021) 19:125

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.